Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000517710 | SCV000612947 | pathogenic | not provided | 2016-10-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000517710 | SCV002238199 | pathogenic | not provided | 2022-08-09 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 447171). This variant has not been reported in the literature in individuals affected with COL4A3-related conditions. This variant is present in population databases (no rsID available, gnomAD 0.007%). This sequence change creates a premature translational stop signal (p.Glu1084*) in the COL4A3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in COL4A3 are known to be pathogenic (PMID: 8956999, 24854265, 26809805, 27281700). |
Gene |
RCV000517710 | SCV005326148 | likely pathogenic | not provided | 2024-03-04 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV005027599 | SCV005653965 | likely pathogenic | Autosomal dominant Alport syndrome; Hematuria, benign familial, 2; Alport syndrome 3b, autosomal recessive | 2024-05-24 | criteria provided, single submitter | clinical testing |